EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
EKF Diagnostics Holdings plc confirms that the Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting have now been published.
The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 20 April 2021 Christopher Mills, Chairman, sold a total of 3,963,591 ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at an average price of 80 pence per Ordinary Share.
Final results for the year ended 31 December 2020
Further to the announcement on 5 August 2020.
Investor briefing 30 March 2021.
EKF Diagnostics confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations.
EKF Diagnostics declares the distribution of shares in Trellus Health Limited.
A General Meeting was held to seek shareholder approval to distribute the company's holding in Trellus Health Limited.